军事知识服务平台
神经梅毒临床路径的临床应用研究
Clinical application of the clinical pathway for neurosyphilis: a pilot study
摘要 目的:报告《神经梅毒临床路径(试行)》的临床应用情况。方法:本研究为前瞻性、多中心、非对照的实施性研究。2025年1月至2026年3月期间,于16家中国神经梅毒临床监测哨点/中国"一带一路"皮肤病学专科联盟-神经梅毒研究联盟单位试运行《神经梅毒临床路径(试行)》,采集神经梅毒患者的路径运行效果数据。结果:研究期间共筛查1 703例入院疑诊神经梅毒患者,确诊神经梅毒485例(28.48%)。确诊患者中,无症状神经梅毒占比最高(241/485例,49.69%),有症状神经梅毒中以麻痹性痴呆(95/485例,19.59%)和脊髓痨(59/485例,12.16%)为主。485例确诊患者中438例进入临床路径,入径率90.31%,其中脊髓痨(59/59)和脑脊膜型(17/17)入径率为100%,无症状神经梅毒和其他类型入径率相对较低,分别为87.97%(212/241例)和87.50%(7/8例)。438例入径患者中430例完成路径,完成率98.17%,脊髓痨(59/59例)和其他类型(7/7例)完成率达100%,麻痹性痴呆(80/85例)和脑脊膜型(16/17例)完成率相对较低,均为94.12%。整体变异例数29例(6.62%),其他类型神经梅毒变异率最高(1/7例,14.29%),其次为无症状神经梅毒(17/212例,8.02%)。37例(8.45%)接受多学科诊疗会诊,会诊科室主要涉及神经内科、精神科等,多针对合并复杂症状的病例。结论:《神经梅毒临床路径(试行)》整体运行良好,可进一步推广。
Abstract:
Objective:To evaluate the clinical application performance of the Clinical Pathway for Neurosyphilis (Trial Version) . Methods:This was a prospective, multicenter, uncontrolled implementation study. From January 2025 to March 2026, the Clinical Pathway for Neurosyphilis (Trial Version) was piloted at 16 Chinese neurosyphilis clinical surveillance sentinel sites/member institutions of the Neurosyphilis Research Alliance, the China "Belt and Road" Dermatology Alliance. Data on the performance of the clinical pathway in patients with neurosyphilis were collected. Results:During the study period, a total of 1 703 hospitalized patients with suspected neurosyphilis were screened, and 485 (28.48%) were diagnosed with neurosyphilis. Among the confirmed patients, asymptomatic neurosyphilis was the most common type (241/485, 49.69%) ; among the patients with symptomatic neurosyphilis, general paresis (95/485, 19.59%) and tabes dorsalis (59/485, 12.16%) were the most common clinical forms. Of the 485 confirmed patients, 438 were enrolled in the clinical pathway, corresponding to an entry rate of 90.31%; the entry rates for tabes dorsalis (59/59) and meningeal neurosyphilis (17/17) reached 100%, whereas entry rates for asymptomatic neurosyphilis (212/241, 87.97%) and other types (7/8, 87.50%) were relatively low. Of the 438 enrolled patients, 430 completed the pathway, with a completion rate of 98.17%; the completion rates for tabes dorsalis (59/59) and other types (7/7) reached 100%, whereas those for general paresis (80/85, 94.12%) and meningeal neurosyphilis (16/17, 94.12%) were relatively low. The overall variation rate was 6.62% (29/438) , with the highest variation rate observed in other types of neurosyphilis (1/7, 14.29%) , followed by asymptomatic neurosyphilis (17/212, 8.02%) . Thirty-seven patients (8.45%) received multidisciplinary consultations, primarily by specialists in neurology and psychiatry for complex comorbidities.Conclusion:The Clinical Pathway for Neurosyphilis (Trial Version) generally performed well and can be further promoted.
刊 名 中华皮肤科杂志 ISTICPKU
年,卷(期): 2026, 59(10)
在线出版日期: 2026年10月15日